Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses

Richard A. Koup, Mario Roederer, Laurie Lamoreaux, Jennifer Fischer, Laura Novik, Martha C. Nason, Brenda D. Larkin, Mary E. Enama, Julie E. Ledgerwood, Robert T. Bailer, John R. Mascola, Gary J. Nabel, Barney S. Graham, Margaret McCluskey, Sarah Hubka, Lasonji Holman, Ingelise Gordon, Pamela Edmonds, Steve Rucker, Joseph Casazza & 2 others Andrew Catanzaro, Alan Fix

Research output: Contribution to journalArticle

Abstract

Background: Induction of HIV-1-specific T-cell responses relevant to diverse subtypes is a major goal of HIV vaccine development. Prime-boost regimens using heterologous gene-based vaccine vectors have induced potent, polyfunctional T cell responses in preclinical studies. Methods: The first opportunity to evaluate the immunogenicity of DNA priming followed by recombinant adenovirus serotype 5 (rAd5) boosting was as open-label rollover trials in subjects who had been enrolled in prior studies of HIV-1 specific DNA vaccines. All subjects underwent apheresis before and after rAd5 boosting to characterize in depth the T cell and antibody response induced by the heterologous DNA/rAd5 prime-boost combination. Results: rAd5 boosting was well-tolerated with no serious adverse events. Compared to DNA or rAd5 vaccine alone, sequential DNA/rAd5 administration induced 7-fold higher magnitude Env-biased HIV-1-specific CD8+ T-cell responses and 100-fold greater antibody titers measured by ELISA. There was no significant neutralizing antibody activity against primary isolates. Vaccine-elicited CD4+ and CD8+ T-cells expressed multiple functions and were predominantly long-term (CD127+) central or effector memory T cells and that persisted in blood for >6 months. Epitopes mapped in Gag and Env demonstrated partial cross-clade recognition. Conclusion: Heterologous prime-boost using vector-based gene delivery of vaccine antigens is a potent immunization strategy for inducing both antibody and T-cell responses. Trial Registration: ClinicalTrails.gov NCT00102089, NCT00108654.

Original languageEnglish (US)
Article numbere9015
JournalPLoS One
Volume5
Issue number2
DOIs
StatePublished - Feb 2 2010
Externally publishedYes

Fingerprint

Immunization
T-cells
Human immunodeficiency virus 1
Adenoviridae
HIV-1
immunization
T-lymphocytes
immune response
serotypes
T-Lymphocytes
antibodies
Antibodies
DNA
Recombinant DNA
Vaccines
recombinant DNA
vaccines
Genes
vector vaccines
AIDS Vaccines

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. / Koup, Richard A.; Roederer, Mario; Lamoreaux, Laurie; Fischer, Jennifer; Novik, Laura; Nason, Martha C.; Larkin, Brenda D.; Enama, Mary E.; Ledgerwood, Julie E.; Bailer, Robert T.; Mascola, John R.; Nabel, Gary J.; Graham, Barney S.; McCluskey, Margaret; Hubka, Sarah; Holman, Lasonji; Gordon, Ingelise; Edmonds, Pamela; Rucker, Steve; Casazza, Joseph; Catanzaro, Andrew; Fix, Alan.

In: PLoS One, Vol. 5, No. 2, e9015, 02.02.2010.

Research output: Contribution to journalArticle

Koup, RA, Roederer, M, Lamoreaux, L, Fischer, J, Novik, L, Nason, MC, Larkin, BD, Enama, ME, Ledgerwood, JE, Bailer, RT, Mascola, JR, Nabel, GJ, Graham, BS, McCluskey, M, Hubka, S, Holman, L, Gordon, I, Edmonds, P, Rucker, S, Casazza, J, Catanzaro, A & Fix, A 2010, 'Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses', PLoS One, vol. 5, no. 2, e9015. https://doi.org/10.1371/journal.pone.0009015
Koup, Richard A. ; Roederer, Mario ; Lamoreaux, Laurie ; Fischer, Jennifer ; Novik, Laura ; Nason, Martha C. ; Larkin, Brenda D. ; Enama, Mary E. ; Ledgerwood, Julie E. ; Bailer, Robert T. ; Mascola, John R. ; Nabel, Gary J. ; Graham, Barney S. ; McCluskey, Margaret ; Hubka, Sarah ; Holman, Lasonji ; Gordon, Ingelise ; Edmonds, Pamela ; Rucker, Steve ; Casazza, Joseph ; Catanzaro, Andrew ; Fix, Alan. / Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. In: PLoS One. 2010 ; Vol. 5, No. 2.
@article{b45003a4ba3f4db284d4b25f6b8636b0,
title = "Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses",
abstract = "Background: Induction of HIV-1-specific T-cell responses relevant to diverse subtypes is a major goal of HIV vaccine development. Prime-boost regimens using heterologous gene-based vaccine vectors have induced potent, polyfunctional T cell responses in preclinical studies. Methods: The first opportunity to evaluate the immunogenicity of DNA priming followed by recombinant adenovirus serotype 5 (rAd5) boosting was as open-label rollover trials in subjects who had been enrolled in prior studies of HIV-1 specific DNA vaccines. All subjects underwent apheresis before and after rAd5 boosting to characterize in depth the T cell and antibody response induced by the heterologous DNA/rAd5 prime-boost combination. Results: rAd5 boosting was well-tolerated with no serious adverse events. Compared to DNA or rAd5 vaccine alone, sequential DNA/rAd5 administration induced 7-fold higher magnitude Env-biased HIV-1-specific CD8+ T-cell responses and 100-fold greater antibody titers measured by ELISA. There was no significant neutralizing antibody activity against primary isolates. Vaccine-elicited CD4+ and CD8+ T-cells expressed multiple functions and were predominantly long-term (CD127+) central or effector memory T cells and that persisted in blood for >6 months. Epitopes mapped in Gag and Env demonstrated partial cross-clade recognition. Conclusion: Heterologous prime-boost using vector-based gene delivery of vaccine antigens is a potent immunization strategy for inducing both antibody and T-cell responses. Trial Registration: ClinicalTrails.gov NCT00102089, NCT00108654.",
author = "Koup, {Richard A.} and Mario Roederer and Laurie Lamoreaux and Jennifer Fischer and Laura Novik and Nason, {Martha C.} and Larkin, {Brenda D.} and Enama, {Mary E.} and Ledgerwood, {Julie E.} and Bailer, {Robert T.} and Mascola, {John R.} and Nabel, {Gary J.} and Graham, {Barney S.} and Margaret McCluskey and Sarah Hubka and Lasonji Holman and Ingelise Gordon and Pamela Edmonds and Steve Rucker and Joseph Casazza and Andrew Catanzaro and Alan Fix",
year = "2010",
month = "2",
day = "2",
doi = "10.1371/journal.pone.0009015",
language = "English (US)",
volume = "5",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses

AU - Koup, Richard A.

AU - Roederer, Mario

AU - Lamoreaux, Laurie

AU - Fischer, Jennifer

AU - Novik, Laura

AU - Nason, Martha C.

AU - Larkin, Brenda D.

AU - Enama, Mary E.

AU - Ledgerwood, Julie E.

AU - Bailer, Robert T.

AU - Mascola, John R.

AU - Nabel, Gary J.

AU - Graham, Barney S.

AU - McCluskey, Margaret

AU - Hubka, Sarah

AU - Holman, Lasonji

AU - Gordon, Ingelise

AU - Edmonds, Pamela

AU - Rucker, Steve

AU - Casazza, Joseph

AU - Catanzaro, Andrew

AU - Fix, Alan

PY - 2010/2/2

Y1 - 2010/2/2

N2 - Background: Induction of HIV-1-specific T-cell responses relevant to diverse subtypes is a major goal of HIV vaccine development. Prime-boost regimens using heterologous gene-based vaccine vectors have induced potent, polyfunctional T cell responses in preclinical studies. Methods: The first opportunity to evaluate the immunogenicity of DNA priming followed by recombinant adenovirus serotype 5 (rAd5) boosting was as open-label rollover trials in subjects who had been enrolled in prior studies of HIV-1 specific DNA vaccines. All subjects underwent apheresis before and after rAd5 boosting to characterize in depth the T cell and antibody response induced by the heterologous DNA/rAd5 prime-boost combination. Results: rAd5 boosting was well-tolerated with no serious adverse events. Compared to DNA or rAd5 vaccine alone, sequential DNA/rAd5 administration induced 7-fold higher magnitude Env-biased HIV-1-specific CD8+ T-cell responses and 100-fold greater antibody titers measured by ELISA. There was no significant neutralizing antibody activity against primary isolates. Vaccine-elicited CD4+ and CD8+ T-cells expressed multiple functions and were predominantly long-term (CD127+) central or effector memory T cells and that persisted in blood for >6 months. Epitopes mapped in Gag and Env demonstrated partial cross-clade recognition. Conclusion: Heterologous prime-boost using vector-based gene delivery of vaccine antigens is a potent immunization strategy for inducing both antibody and T-cell responses. Trial Registration: ClinicalTrails.gov NCT00102089, NCT00108654.

AB - Background: Induction of HIV-1-specific T-cell responses relevant to diverse subtypes is a major goal of HIV vaccine development. Prime-boost regimens using heterologous gene-based vaccine vectors have induced potent, polyfunctional T cell responses in preclinical studies. Methods: The first opportunity to evaluate the immunogenicity of DNA priming followed by recombinant adenovirus serotype 5 (rAd5) boosting was as open-label rollover trials in subjects who had been enrolled in prior studies of HIV-1 specific DNA vaccines. All subjects underwent apheresis before and after rAd5 boosting to characterize in depth the T cell and antibody response induced by the heterologous DNA/rAd5 prime-boost combination. Results: rAd5 boosting was well-tolerated with no serious adverse events. Compared to DNA or rAd5 vaccine alone, sequential DNA/rAd5 administration induced 7-fold higher magnitude Env-biased HIV-1-specific CD8+ T-cell responses and 100-fold greater antibody titers measured by ELISA. There was no significant neutralizing antibody activity against primary isolates. Vaccine-elicited CD4+ and CD8+ T-cells expressed multiple functions and were predominantly long-term (CD127+) central or effector memory T cells and that persisted in blood for >6 months. Epitopes mapped in Gag and Env demonstrated partial cross-clade recognition. Conclusion: Heterologous prime-boost using vector-based gene delivery of vaccine antigens is a potent immunization strategy for inducing both antibody and T-cell responses. Trial Registration: ClinicalTrails.gov NCT00102089, NCT00108654.

UR - http://www.scopus.com/inward/record.url?scp=77749322238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749322238&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0009015

DO - 10.1371/journal.pone.0009015

M3 - Article

VL - 5

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e9015

ER -